May 29, 2015 - An investigation on behalf of current long-term investors in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares was announced over potential breaches of fiduciary duties by certain officers and directors at Vertex Pharmaceuticals.

The investigation by a law firm concerns whether certain Vertex Pharmaceuticals officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.

Vertex Pharmaceuticals Incorporated reported that its annual Total Revenue declined from over $1.52 billion in 2012 to $580.41 million in 2014 and that its Net Loss of $107.03 million in 2012 increased to a Net Loss of $738.55 million in 2014. Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) grew from $38.88 per share in December 2012 to as high as $135.82 per share in April 2015.
On May 26, 2015, it was reported that two leading advisory firms are recommending that shareholders vote against executive pay packages at Vertex Pharmaceuticals Inc., calling aspects of last years compensation at Vertex Pharmaceuticals Incorporated excessive and exorbitant.
On May 29, 2015, NASDAQ:VRTX shares closed at $128.29 per share.